MIPS Project Detail:

Company
Company Description:
Rexahn Pharmaceuticals Inc. is a publicly traded clinical stage pharmaceutical company dedicated to commercializing first-in-class and best-in-class therapeutics for cancer and central nervous system (CNS) disorders. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™—all potential best-in-class therapeutics. Rexahn also operates key R&D programs of nanomedicines, 3D-GOLD and TIMES drug discovery platforms.

MIPS Project
Ligand screening for novel anticancer therapeutics
Project #
3501
|
MIPS Round
35
|
Starting Date:
Feb 2005
Principal Investigator:
John
Orban
,
,
Project Manager:
Chang
Ahn
,
,
Chairman/Chief Executive Officer
Technologies:
Biotechnology / Genetic Engineering